Clinical trial
Phase II Trial of Irinotecan in Children With Refractory Solid Tumors
NCT00004078 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of Irinotecan in Children With Refractory Solid Tumors
- Lead sponsor
- Children's Oncology Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 1999
- Completion date
- Not reported
- Enrollment
- 181 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
childhood central nervous system germ cell tumor, childhood choroid plexus tumor, childhood craniopharyngioma, childhood grade i meningioma, childhood grade ii meningioma, childhood grade iii meningioma, childhood infratentorial ependymoma, childhood oligodendroglioma, childhood supratentorial ependymoma, previously treated childhood rhabdomyosarcoma, recurrent childhood cerebellar astrocytoma, recurrent childhood cerebral astrocytoma, recurrent childhood ependymoma, recurrent childhood medulloblastoma, recurrent childhood rhabdomyosarcoma, recurrent childhood visual pathway and hypothalamic glioma, recurrent childhood visual pathway glioma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent neuroblastoma, recurrent osteosarcoma, unspecified childhood solid tumor, protocol specific